Huang Linfei, Wei Meng, Li Huilong, Yu Mingxin, Wan Luming, Zhao Ruzhou, Gao Qi, Sun Lijuan, Hou Xufeng, Mo Yunhai, Huang Qing, Zhen Lan, Yang Xiaopan, Li Jingfei, Wang Nan, Zhang Chundong, Jin Haoran, Zhou Li, Xu Yixin, Lin Haotian, Zhang Xuhui, Li Boan, Han Yue, Yuan Jing, Zhang Rui, Wu Feixiang, Zhong Hui, Wei Congwen
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, No. 20 Dongdajie, Fengtai District, Beijing, 100071, China.
Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Qingxiu District, Nanning, Guangxi, 530021, China.
Mol Cancer. 2025 May 26;24(1):151. doi: 10.1186/s12943-025-02350-6.
Colorectal cancer (CRC) liver metastasis is the main cause of cancer-related mortality. How liver influences intercellular communication to support CRC liver metastasis remains unknown. Herein, we link GP73, whose chronic upregulation in hepatocytes triggers non-obese metabolic-dysfunction associated steatotic liver disease (MASLD) in mice, with exosome biogenesis and CRC liver metastasis. Mice with high liver GP73 expression exhibited increased CRC liver metastasis in an exosome-dependent manner. GP73 modulated the cholesterol contents in endosomal compartments to promote exosome production. Quantitative proteomics revealed GP73 reshaped hepatocyte exosomal proteome and produced NAV2-rich exosomes. Clinically, serum GP73 levels positively correlated with exosomal NAV2 levels in CRC patients with liver metastasis. Knockdown of liver NAV2 suppressed enhanced CRC liver metastasis in GP73-induced non-obese mice, and GP73 blockade mitigated the increased CRC liver metastasis in obese mice fed by high-fat diet or high-fructose diet. Our findings suggest GP73 blockade as a potential therapeutic strategy for mitigating CRC liver metastasis.
结直肠癌(CRC)肝转移是癌症相关死亡的主要原因。肝脏如何影响细胞间通讯以支持CRC肝转移仍不清楚。在此,我们将GP73与外泌体生物发生和CRC肝转移联系起来,GP73在肝细胞中的慢性上调会引发小鼠非肥胖代谢功能障碍相关脂肪性肝病(MASLD)。肝脏GP73表达高的小鼠以依赖外泌体的方式表现出CRC肝转移增加。GP73调节内体区室中的胆固醇含量以促进外泌体产生。定量蛋白质组学显示GP73重塑了肝细胞外泌体蛋白质组并产生了富含NAV2的外泌体。在临床上,CRC肝转移患者的血清GP73水平与外泌体NAV2水平呈正相关。敲低肝脏中的NAV2可抑制GP73诱导的非肥胖小鼠中增强的CRC肝转移,而阻断GP73可减轻高脂饮食或高果糖饮食喂养的肥胖小鼠中增加的CRC肝转移。我们的研究结果表明,阻断GP73是减轻CRC肝转移的一种潜在治疗策略。